Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Esperion Therapeutics’ regulatory disclosures blend dense cardiovascular science with intricate royalty agreements. Searching a 300-page 10-K for bempedoic acid sales projections or scanning Form 4s to see when executives exercise options can take hours. That’s exactly why investors ask, "Where can I find Esperion Therapeutics' quarterly earnings report 10-Q filing?" or "How do I track Esperion Therapeutics insider trading Form 4 transactions in real time?" Stock Titan answers in seconds.
Our platform delivers AI-powered summaries so you can start understanding Esperion Therapeutics SEC documents with AI rather than reading line by line. Real-time alerts surface Esperion Therapeutics Form 4 insider transactions real-time, while side-by-side comparisons turn each Esperion Therapeutics quarterly earnings report 10-Q filing into an at-a-glance trend chart. Need the story behind a sudden milestone payment? Our AI links the related Esperion Therapeutics 8-K material events explained to management commentary, giving context that traditional databases miss. And because we track every form—10-K, 10-Q, 8-K, Form 4, S-1, DEF 14A—you never miss a disclosure.
You’ll also get a simplified view of the Esperion Therapeutics annual report 10-K simplified, a deep dive into the Esperion Therapeutics proxy statement executive compensation, and an Esperion Therapeutics earnings report filing analysis that highlights R&D spending on next-generation LDL-C therapies. Every document—from insider trading Form 4s to 8-K clinical-trial updates—arrives within moments of hitting EDGAR. Stop piecing together fragments; rely on Stock Titan’s expert analysis to see the full picture of Esperion’s drug commercialization, cash runway, and Esperion Therapeutics executive stock transactions Form 4 in one place.
Esperion Therapeutics filed an Amendment No. 1 to its Form 8-K to correct its August 5, 2025 earnings release. The amendment corrects the Balance Sheet Data for the period ended June 30, 2025 and the Statement of Operations for the three and six months ended June 30, 2025, specifically net income (loss), net income (loss) per share, and income from operations for the three-month period. A corrected earnings release is furnished as Exhibit 99.1 dated August 11, 2025. Management states these figures are preliminary, unaudited, and subject to completion of the quarter-end close and may change; all other disclosures remain unchanged.
Esperion Therapeutics (ESPR) – Form 4 filing: On 07/01/2025 director John Craig Thompson received an option grant for 40,000 shares of common stock at an exercise price of $1.00 per share. The options vest in three equal annual installments beginning 07/01/2026 and expire on 07/01/2035. No common shares were bought or sold; the transaction is classified as an "A" (grant) and the beneficial ownership is reported as direct. Following the grant, Thompson beneficially owns 40,000 derivative securities (options) and no change was reported in non-derivative share ownership.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) has appointed Craig Thompson, MBA, a veteran biotechnology executive, to its Board of Directors effective July 1, 2025. Thompson will serve as an independent Class II director with a term running through the 2027 annual meeting. He will immediately join the Compliance, Nominating & Corporate Governance, and Commercial Committees.
Thompson brings more than two decades of commercial and C-suite experience to Esperion. He is currently CEO of Cerevance, LLC and holds board seats at NervGen Pharma. His prior leadership roles include CEO positions at Neurana, Anthera and senior commercial posts at Tetraphase, Trius, Pfizer and Merck, where he helped launch high-profile cardiovascular products such as Zocor and oversaw the global commercial development of torcetrapib/atorvastatin.
Under Esperion’s non-employee director compensation plan, Thompson will receive standard cash retainers and equity awards. The company has executed a customary indemnification agreement with him. No related-party transactions were disclosed.
A press release announcing the appointment was furnished as Exhibit 99.1 under Item 7.01; the disclosure is deemed “furnished” and not “filed” under the Exchange Act.
The Form 4 filed on 18 June 2025 shows that Esperion Therapeutics (ESPR) General Counsel Benjamin Looker sold 6,422 common shares on 17 June 2025 at an average price of $1.152 per share. A footnote clarifies the disposition was made solely to cover withholding taxes on recently vested RSUs, and the transaction was coded “S.” After the sale, Looker continues to hold 401,241 ESPR shares directly, meaning the divestiture equals roughly 1.6 % of his post-transaction stake. No derivative securities were exercised or disposed of.
Because the sale is small relative to the insider’s total ownership and is expressly tax-related, it is typically regarded as routine and low-impact for valuation or governance considerations. Nevertheless, investors tracking insider sentiment may note that the execution price signals the insider’s willingness to transact around the $1.15 level.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
